NASDAQ:DCPH

Deciphera Pharmaceuticals Competitors

$43.81
-0.60 (-1.35 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$43.11
Now: $43.81
$44.18
50-Day Range
$40.39
MA: $43.81
$46.21
52-Week Range
$39.42
Now: $43.81
$68.40
Volume232,071 shs
Average Volume442,447 shs
Market Capitalization$2.52 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.49

Competitors

Deciphera Pharmaceuticals (NASDAQ:DCPH) Vs. JAZZ, UTHR, MRVI, MRTX, BBIO, and RARE

Should you be buying DCPH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Deciphera Pharmaceuticals, including Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Maravai LifeSciences (MRVI), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), and Ultragenyx Pharmaceutical (RARE).

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Jazz Pharmaceuticals and Deciphera Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111502.82
Deciphera Pharmaceuticals03702.70

Jazz Pharmaceuticals presently has a consensus target price of $185.8824, suggesting a potential upside of 15.17%. Deciphera Pharmaceuticals has a consensus target price of $70.30, suggesting a potential upside of 60.47%. Given Deciphera Pharmaceuticals' higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than Jazz Pharmaceuticals.

Insider & Institutional Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 7.0% of Deciphera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Jazz Pharmaceuticals and Deciphera Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.21$523.37 million$14.6011.05
Deciphera Pharmaceuticals$25 million100.98$-192,260,000.00($4.48)-9.78

Jazz Pharmaceuticals has higher revenue and earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jazz Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.

Profitability

This table compares Jazz Pharmaceuticals and Deciphera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Deciphera PharmaceuticalsN/A-45.02%-40.12%

Summary

Jazz Pharmaceuticals beats Deciphera Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

United Therapeutics (NASDAQ:UTHR) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for United Therapeutics and Deciphera Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United Therapeutics00703.00
Deciphera Pharmaceuticals03702.70

United Therapeutics presently has a consensus target price of $219.5714, suggesting a potential upside of 7.97%. Deciphera Pharmaceuticals has a consensus target price of $70.30, suggesting a potential upside of 60.47%. Given Deciphera Pharmaceuticals' higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than United Therapeutics.

Insider & Institutional Ownership

90.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. 10.9% of United Therapeutics shares are owned by insiders. Comparatively, 7.0% of Deciphera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares United Therapeutics and Deciphera Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$1.45 billion6.25$-104,500,000.00($2.39)-85.09
Deciphera Pharmaceuticals$25 million100.98$-192,260,000.00($4.48)-9.78

United Therapeutics has higher revenue and earnings than Deciphera Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

United Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.

Profitability

This table compares United Therapeutics and Deciphera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United Therapeutics33.25%15.48%11.31%
Deciphera PharmaceuticalsN/A-45.02%-40.12%

Summary

United Therapeutics beats Deciphera Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Maravai LifeSciences and Deciphera Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
Deciphera Pharmaceuticals03702.70

Maravai LifeSciences presently has a consensus target price of $38.1250, suggesting a potential upside of 10.00%. Deciphera Pharmaceuticals has a consensus target price of $70.30, suggesting a potential upside of 60.47%. Given Deciphera Pharmaceuticals' higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than Maravai LifeSciences.

Insider & Institutional Ownership

73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. 7.0% of Deciphera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Maravai LifeSciences and Deciphera Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
Deciphera Pharmaceuticals$25 million100.98$-192,260,000.00($4.48)-9.78

Maravai LifeSciences has higher earnings, but lower revenue than Deciphera Pharmaceuticals.

Profitability

This table compares Maravai LifeSciences and Deciphera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
Deciphera PharmaceuticalsN/A-45.02%-40.12%

Mirati Therapeutics (NASDAQ:MRTX) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Earnings and Valuation

This table compares Mirati Therapeutics and Deciphera Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirati Therapeutics$3.34 million2,579.76$-213,260,000.00($5.69)-29.91
Deciphera Pharmaceuticals$25 million100.98$-192,260,000.00($4.48)-9.78

Deciphera Pharmaceuticals has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mirati Therapeutics and Deciphera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirati TherapeuticsN/A-60.01%-54.21%
Deciphera PharmaceuticalsN/A-45.02%-40.12%

Insider & Institutional Ownership

94.9% of Mirati Therapeutics shares are owned by institutional investors. Comparatively, 73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. 4.1% of Mirati Therapeutics shares are owned by insiders. Comparatively, 7.0% of Deciphera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Mirati Therapeutics has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Mirati Therapeutics and Deciphera Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirati Therapeutics151002.56
Deciphera Pharmaceuticals03702.70

Mirati Therapeutics presently has a consensus target price of $218.5714, suggesting a potential upside of 28.44%. Deciphera Pharmaceuticals has a consensus target price of $70.30, suggesting a potential upside of 60.47%. Given Deciphera Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than Mirati Therapeutics.

Summary

Deciphera Pharmaceuticals beats Mirati Therapeutics on 9 of the 13 factors compared between the two stocks.

BridgeBio Pharma (NASDAQ:BBIO) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares BridgeBio Pharma and Deciphera Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$40.56 million200.11$-260,590,000.00($2.48)-21.97
Deciphera Pharmaceuticals$25 million100.98$-192,260,000.00($4.48)-9.78

Deciphera Pharmaceuticals has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BridgeBio Pharma and Deciphera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BridgeBio PharmaN/A-109.88%-48.54%
Deciphera PharmaceuticalsN/A-45.02%-40.12%

Institutional & Insider Ownership

95.5% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. 40.3% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 7.0% of Deciphera Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

BridgeBio Pharma has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for BridgeBio Pharma and Deciphera Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BridgeBio Pharma01902.90
Deciphera Pharmaceuticals03702.70

BridgeBio Pharma presently has a consensus price target of $72.8889, suggesting a potential upside of 33.77%. Deciphera Pharmaceuticals has a consensus price target of $70.30, suggesting a potential upside of 60.47%. Given Deciphera Pharmaceuticals' higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than BridgeBio Pharma.

Summary

BridgeBio Pharma beats Deciphera Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Ultragenyx Pharmaceutical and Deciphera Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million66.80$-402,730,000.00($7.36)-14.06
Deciphera Pharmaceuticals$25 million100.98$-192,260,000.00($4.48)-9.78

Deciphera Pharmaceuticals has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ultragenyx Pharmaceutical and Deciphera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%
Deciphera PharmaceuticalsN/A-45.02%-40.12%

Institutional & Insider Ownership

73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 7.0% of Deciphera Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ultragenyx Pharmaceutical and Deciphera Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical06802.57
Deciphera Pharmaceuticals03702.70

Ultragenyx Pharmaceutical presently has a consensus price target of $131.20, suggesting a potential upside of 26.79%. Deciphera Pharmaceuticals has a consensus price target of $70.30, suggesting a potential upside of 60.47%. Given Deciphera Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than Ultragenyx Pharmaceutical.

Summary

Deciphera Pharmaceuticals beats Ultragenyx Pharmaceutical on 9 of the 14 factors compared between the two stocks.


Deciphera Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$161.40-0.3%$9.09 billion$2.16 billion50.91Insider Selling
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.36-1.3%$9.06 billion$1.45 billion19.24Analyst Report
Analyst Revision
News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$34.66-4.1%$8.93 billionN/A0.00Analyst Downgrade
News Coverage
Gap Up
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$170.17-1.8%$8.62 billion$3.34 million-22.10Insider Selling
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.49-6.7%$8.12 billion$40.56 million-15.98Analyst Report
Gap Down
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$103.48-3.0%$6.93 billion$103.71 million-23.57News Coverage
Gap Down
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$217.93-0.0%$6.83 billion$311.33 million-126.70Insider Selling
News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$125.61-3.1%$6.75 billion$14.98 million-15.30Gap Down
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$62.15-2.5%$6.45 billion$87.99 million-73.99News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.79-4.3%$6.30 billion$150,000.00-21.13News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36-0.8%$5.97 billion$1.12 billion88.25
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.54-1.3%$5.60 billion$380.83 million-9.02
Allakos logo
ALLK
Allakos
1.7$105.00-2.9%$5.58 billionN/A-38.32Insider Selling
Gap Down
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.16-0.1%$5.46 billion$66.51 million17.37
Perrigo logo
PRGO
Perrigo
2.5$40.53-0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.5$73.90-4.1%$5.17 billion$85.54 million0.00Insider Selling
Gap Down
Galapagos logo
GLPG
Galapagos
1.3$77.81-0.1%$5.10 billion$1.00 billion-11.79
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$56.51-0.5%$4.68 billionN/A0.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61-0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39-2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
News Coverage
Gap Down
LEGN
Legend Biotech
1.2$28.45-6.5%$3.76 billion$64.39 million0.00Gap Down
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60News Coverage
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.